Sara Hurvitz discusses additional results from the ASCENT study showing favorable outcomes with sacituzumab govitecan in patients with metastatic triple-negative breast cancer regardless of biomarker status (5:24).
10-12-2020 | SABCS 2020 | Conference coverage | Video